DanCann Pharma A/S publishes Q1-2022 report: Facing commercialization stage
COPENHAGEN, Denmark, 18 May 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the first quarter of 2022. The Q1-2022 report is available as an attached document to this press release and at www.dancann.com.Group key figures Q1-2022: KDKK 01/01/22 01/01/21 01/01/21 01/01/20 31/03/22 31/03/21 31/12/21 31/12/20Net sales 1,266 0 874 0Operating profit (EBIT) -3,549 -2,591